Skip to main content

Table 1 Study population characteristics (n = 36)

From: Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

Median [range] age (yr) 55 [37-87]
Histotype #  
   Invasive ductal carcinoma 28 (77.7%)
   Invasive lobular carcinoma 5 (13.8%)
   Mixed (ductal and lobular) 2 (5.5%)
   Undifferentiated 1 (3.0%)
Grading°  
   G2 21 (58.3%)
   G3 15 (41.7%)
ER status  
   Negative 14 (38.8%)
   Positive 22 (61.2%)
PgR status  
   Negative 13 (36.1%)
   Positive 23 (63.9%)
HER2 status*  
   Negative 27 (75.0%)
   Positive 9 (25.0%)
Adjuvant chemotherapy^  
   FEC 18 (52.9%)
   EC 11 (32.4%)
   CMF 5 (14.7%)
Mean ± SD time to first relapse (months) 15.8 ± 6.5
Metastatis sites  
   Bone 21 (58.3%)
   Liver 21 (58.3%)
   Lung 16 (44.4%)
   Lymphnodes 14 (38.8%)
   Local 3 (8.3%)
Chemotherapy"  
   TXT75 14 (38.8%)
   TXT25 8 (22.2%)
   TXT75+C 5 (13.8%)
   TXT75+T 9 (25.2%)
Treatment best response  
   Complete response 1 (2.7%)
   Partial response 14 (38.8%)
   Stable disease 12 (33.3%)
   Disease progression 9 (25.2%)
Time to disease progression (months)  
   Median [range] 9 [2-54]
Overall survival (months)  
   Median [range] 20 [3-101]
  1. #According to WHO hystological typing of breast tumor (Ref. 32). °According to Elston and Ellis classification (Ref. 31). *Pre-study determination. "See text for regimen details. ^ on 34 pts.